# TAL2

## Overview
TAL2 is a gene that encodes the TAL bHLH transcription factor 2, a member of the basic helix-loop-helix (bHLH) family of transcription factors. This protein is characterized by its conserved bHLH domain, which is essential for DNA binding and dimerization, allowing it to regulate gene expression during developmental processes, particularly in the nervous system (Choudhury2023InSilico; Xia1991TAL2). TAL2 plays a crucial role in neural differentiation and is involved in the regulation of neurogenesis and hematopoiesis. Its expression is tightly regulated during embryonic development, suggesting a significant role in early brain development and neural fate determination (Kobayashi2014Tal2). Additionally, TAL2 is implicated in T-cell acute lymphoblastic leukemia (T-ALL), where it can be involved in chromosomal translocations that contribute to leukemogenesis, highlighting its potential role as a proto-oncogene (van2007Prognostic; Xia1991TAL2).

## Structure
The TAL2 gene encodes a protein that is part of the basic helix-loop-helix (bHLH) family of transcription factors, characterized by a conserved bHLH domain crucial for DNA binding and dimerization. The primary structure of TAL2 includes a sequence of amino acids forming a helix-loop-helix (HLH) domain, which is highly conserved and shares significant sequence homology with other HLH proteins such as TAL1 and LYL1 (Choudhury2023InSilico; Xia1991TAL2). This domain consists of two amphipathic alpha-helices connected by a loop, facilitating dimerization and interaction with DNA at E-box motifs (Xia1991TAL2).

The secondary structure of the TAL2 protein is defined by these alpha-helices, which are typical of HLH proteins. The tertiary structure, while not explicitly detailed, likely involves the folding of these helices to enable functional interactions with other proteins and DNA. The quaternary structure may involve the formation of heterologous complexes with other HLH proteins, such as E47 and E12, enhancing its role in transcriptional regulation (Xia1991TAL2).

Post-translational modifications, such as phosphorylation, may influence the function and interactions of the TAL2 protein, although specific modifications are not detailed in the available context. The presence of splice variant isoforms is not mentioned in the provided information.

## Function
The TAL2 gene encodes a transcription factor that is part of the basic helix-loop-helix (bHLH) family, which plays a significant role in regulating gene expression during development, particularly in the nervous system. TAL2 is involved in neural differentiation, where its expression is induced by all-trans retinoic acid (atRA) in P19 pluripotent mouse embryonal carcinoma cells, a model for studying neural differentiation (Kobayashi2014Tal2; Kobayashi2015Transcriptional). The TAL2 protein is primarily active in the nucleus, where it binds to specific DNA sequences to modulate transcription, influencing processes like neurogenesis and hematopoiesis (Kobayashi2014Tal2).

In healthy cells, TAL2 expression is transient during embryonic development, suggesting its involvement in early brain development and the acquisition of neural fate (Kobayashi2014Tal2). The gene's expression is regulated by retinoic acid receptors (RARs) and retinoid X receptors (RXRs), which form heterodimers to control gene transcription in response to atRA signaling (Kobayashi2014Tal2). This regulation is crucial for neural differentiation and brain patterning, highlighting TAL2's role in the development of the nervous system (Kobayashi2015Transcriptional).

## Clinical Significance
The TAL2 gene is implicated in T-cell acute lymphoblastic leukemia (T-ALL), a high-risk malignancy of thymocytes. In T-ALL, TAL2 is involved in chromosomal translocations, which are significant genetic alterations contributing to the disease's progression (van2007Prognostic). These translocations can lead to the overexpression of TAL2, which is associated with a differentiation arrest in lymphocytes, classifying T-ALL into different subtypes based on genetic characteristics (Genescà2022Latest). TAL2, along with other transcription factors like TAL1 and LYL1, is part of the TALLMO subtypes of T-ALL, characterized by rearrangements involving these genes (Kroeze2020Tcell).

While TAL2 is less frequently rearranged compared to other genes like TAL1, its involvement in T-ALL suggests it plays a role in the disease's pathogenesis. The clinical significance of TAL2 mutations specifically is not well-defined, but its aberrant expression is linked to the broader context of genetic abnormalities in T-ALL (van2007Prognostic). The precise impact of TAL2 on clinical outcomes in T-ALL remains an area of ongoing research, with its role in transcriptional regulation being a key factor in the disease's development.

## Interactions
The TAL2 gene, a member of the basic helix-loop-helix (bHLH) family, is involved in various protein interactions that are crucial for its function as a transcription factor. TAL2 can form heterodimers with other bHLH proteins, such as E12 and E47, which are products of the E2A gene. These heterodimers specifically bind to the E-box motif (CANNTG) in DNA, influencing transcriptional regulation (Choudhury2023InSilico; Xia1991TAL2). The interaction with E proteins allows TAL2 to participate in transcriptional regulation by recognizing and binding to specific DNA sequences, thereby modulating gene expression.

In the context of T-cell acute lymphoblastic leukemia (T-ALL), TAL2 is involved in interactions with several other molecules, including TCF3, GATA1, HELT, CITED2, FKTN, EPB42, TLX1, LMO2, and LMO1. These interactions are significant for understanding the role of TAL2 in leukemogenesis (Choudhury2023InSilico). The TAL2 gene is also transcriptionally activated by the t(7;9)(q34;q32) translocation, which is associated with T-ALL, suggesting its role as a proto-oncogene (Xia1991TAL2). These interactions highlight the importance of TAL2 in both normal cellular processes and disease states.


## References


[1. (Kobayashi2014Tal2) Takanobu Kobayashi, Rie Komori, Kiyoshi Ishida, Katsuhito Kino, Sei-ichi Tanuma, and Hiroshi Miyazawa. Tal2 expression is induced by all-trans retinoic acid in p19 cells prior to acquisition of neural fate. Scientific Reports, May 2014. URL: http://dx.doi.org/10.1038/srep04935, doi:10.1038/srep04935. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep04935)

[2. (Genescà2022Latest) Eulàlia Genescà and Celia González-Gil. Latest contributions of genomics to t-cell acute lymphoblastic leukemia (t-all). Cancers, 14(10):2474, May 2022. URL: http://dx.doi.org/10.3390/cancers14102474, doi:10.3390/cancers14102474. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers14102474)

[3. (Kobayashi2015Transcriptional) Takanobu Kobayashi, Masayo Suzuki, Masayuki Morikawa, Katsuhito Kino, Sei-ichi Tanuma, and Hiroshi Miyazawa. Transcriptional regulation of &lt;i&gt;tal2&lt;/i&gt; gene by all-&lt;i&gt;trans&lt;/i&gt; retinoic acid (atra) in p19 cells. Biological and Pharmaceutical Bulletin, 38(2):248–256, 2015. URL: http://dx.doi.org/10.1248/bpb.b14-00617, doi:10.1248/bpb.b14-00617. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1248/bpb.b14-00617)

[4. (van2007Prognostic) M van Grotel, J P P Meijerink, E R van Wering, A W Langerak, H B Beverloo, J G C A M Buijs-Gladdines, N B Burger, M Passier, E M van Lieshout, W A Kamps, A J P Veerman, M M van Noesel, and R Pieters. Prognostic significance of molecular-cytogenetic abnormalities in pediatric t-all is not explained by immunophenotypic differences. Leukemia, 22(1):124–131, October 2007. URL: http://dx.doi.org/10.1038/sj.leu.2404957, doi:10.1038/sj.leu.2404957. This article has 106 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/sj.leu.2404957)

[5. (Kroeze2020Tcell) Emma Kroeze, Jan L. C. Loeffen, Vera M. Poort, and Jules P. P. Meijerink. T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor? Blood Advances, 4(14):3466–3473, July 2020. URL: http://dx.doi.org/10.1182/bloodadvances.2020001822, doi:10.1182/bloodadvances.2020001822. This article has 37 citations and is from a peer-reviewed journal.](https://doi.org/10.1182/bloodadvances.2020001822)

6. (Choudhury2023InSilico) In-Silico analysis of TAL1, TAL2 and LYL1 gene associated with T-ALL. This article has 0 citations.

[7. (Xia1991TAL2) Y Xia, L Brown, C Y Yang, J T Tsan, M J Siciliano, R Espinosa, M M Le Beau, and R J Baer. Tal2, a helix-loop-helix gene activated by the (7;9)(q34;q32) translocation in human t-cell leukemia. Proceedings of the National Academy of Sciences, 88(24):11416–11420, December 1991. URL: http://dx.doi.org/10.1073/pnas.88.24.11416, doi:10.1073/pnas.88.24.11416. This article has 144 citations.](https://doi.org/10.1073/pnas.88.24.11416)